Xenetic Biosciences (XBIO) Assets Average (2012 - 2026)
Xenetic Biosciences' (XBIO) quarterly Assets Average came in at $8.1 million in Q1 2026, up 28.21% YoY from $6.3 million in Q1 2025, and up 21.15% on a QoQ basis from $6.7 million in Q4 2025.
Xenetic Biosciences (XBIO) Assets Average (2012 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 15 years of Assets Average data on file, last reported at $8.1 million in Q1 2026.
- Quarterly Assets Average rose 28.21% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (up 28.21% YoY) and the FY2025 annual result came in at $7.6 million, down 12.8% from the prior year.
- Assets Average advanced to $8.1 million in Q1 2026, from $6.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $18.9 million in Q1 2022 to a low of $5.2 million in Q3 2025.
- A 5-year average of $10.9 million and a median of $10.0 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 51.92% — and 2025, when it plunged 39.52%.
- Tracing XBIO's Assets Average over 5 years: stood at $15.1 million in 2022, then slipped by 25.51% to $11.3 million in 2023, then sank by 33.76% to $7.5 million in 2024, then fell by 10.14% to $6.7 million in 2025, then rose by 21.15% to $8.1 million in 2026.
- The last three Assets Average figures came in at $8.1 million (Q1 2026), $6.7 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | 7.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.44 Mn |
| Mar 31, 2026 | 8.14 Mn |
| Dec 31, 2025 | 6.72 Mn |
| Sep 30, 2025 | 5.21 Mn |
| Jun 30, 2025 | 5.57 Mn |
| Mar 31, 2025 | 6.35 Mn |
| Dec 31, 2024 | 7.47 Mn |
| Sep 30, 2024 | 8.54 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | 11.28 Mn |
| Sep 30, 2023 | 12.36 Mn |
| Jun 30, 2023 | 13.23 Mn |
| Mar 31, 2023 | 14.22 Mn |
| Dec 31, 2022 | 15.15 Mn |
| Sep 30, 2022 | 16.02 Mn |
| Jun 30, 2022 | 17.23 Mn |
| Mar 31, 2022 | 18.90 Mn |
| Dec 31, 2021 | 20.55 Mn |
| Sep 30, 2021 | 16.10 Mn |